The UK and US have reached a key trade agreement that will maintain zero duties on British pharmaceutical products going into the American market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to raise spending on pharmaceuticals through the public health system. This pledge ensures that duties on these vital exports will stay at nothing for a timeframe of the next three years.
This agreement follows earlier threats to hike import taxes on patented pharmaceutical imports, with figures mentioned as high as one hundred percent.
"This arrangement between the Britain bolsters the worldwide climate for new treatments and establishes long-overdue equity to U.S.–U.K. medicine commerce," a release declared.
Commercial Significance
Medicines represent one of the the United Kingdom's biggest goods shipped to the US, which is easily the biggest market for leading British pharmaceutical firms.
Statistics reveal that in the 12 months prior to the third quarter, the UK sold drugs valued at £11.1bn to the US. This value accounted for 17.4% of all goods exports in that span.
"This deal protects employment, boosts capital expenditure and facilitates the UK to become a worldwide center for medical research," a government official remarked.
Specific UK Commitments
The agreement entails several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it considers new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to increase total health service expenditure on medicines from 0.3 percent of the national economy to 0.6% over the next decade.
- Payback Limit: The percentage drug companies must return to the NHS to control costs will be restricted at fifteen percent. In the past, rebates were more than 20%.
Industry Background
The deal follows a ongoing tension between the pharmaceutical industry and the ministers over drug pricing and NHS adoption.
The disagreement were intensified by arguments that American customers were charged several times more for the same drugs than patients in the UK and Europe.
Recently, several significant manufacturing plans in the UK have been halted or abandoned, while substantial investments have been announced toward projects in the United States.
The Science Minister stated that the NHS must spend more on treatments, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the previous ten-year period.
